The androgen receptor in prostate cancer cells can activate different sets of genes depending on whether it binds with an androgen hormone or an antiandrogen drug, according to a new study led by researchers at The Ohio State University, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. The study found that when androgen receptor (AR) binds with testosterone or dihydrotestosterone, the activated … Continue reading Study maps why different sets of genes are activated by androgen receptor in prostate cancer cells.